A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
2.
USE OF COMPOUND IN PREVENTION OR TREATMENT OF RADIATION-INDUCED BRAIN INJURY
A use of 5α-androstane-3β,5,6β-triol and a derivative thereof in prevention or treatment of radiation-induced brain injury, and a method for preventing or treating radiation-induced brain injury using 5α-androstane-3β,5,6β-triol and the derivative thereof.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 25/00 - Drugs for disorders of the nervous system
3.
Hexokinase 2-specific inhibitors for use in acute central nervous system injury
Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.
Disclosed is use of 5α-androst-3β,5,6β-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pulmonary disease in a patient. These compounds can significantly inhibit the up-regulation of PFKFB3 expression, significantly inhibit the accumulation of lactate, significantly reduce vascular endothelial cell injury, significantly reduce alveolar epithelial cell injury, significantly inhibit alveolar septum thickening, significantly reduce alveolar damage, and thus can be used to treat diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury, such as in the lung.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 11/00 - Drugs for disorders of the respiratory system
A health-care composition for increasing HDL-C. The composition comprises the following components in percentages by weight: 30-46% of red yeast rice; 10-28% of Ginkgo biloba leaf extract; 0.0005-0.056% of folic acid; 0.001-0.2% of vitamin B6; and 40-50% of an excipient. Compared with the composition of red yeast rice and Ginkgo biloba leaf extract, the health-care composition which has folic acid and vitamin B6 further added thereto can not only significantly reduce the levels of TG, TC and LDL-C in serum, but can also significantly improve the level of HDL-C, so that the health-care composition can more effectively regulate blood fat and be used for preventing various cardiovascular diseases caused by dyslipidemia.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications of 5α-androst-3β,5,6β-triol and an analog thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt thereof in preparing a drug for treating a pulmonary disease of a patient. These compounds can remarkably inhibit up-regulated expression of PFKFB3, remarkably inhibit accumulation of lactic acid, remarkably reduce vascular endothelial cell injury, remarkably reduce alveolar epithelial cell injury, remarkably inhibit thickening of an alveolar septum, and remarkably reduce alveolar injury, so that these compounds can be used for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
Disclosed is a use of 5α-androstane-3β,5,6β-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/00 - Drugs for disorders of the nervous system
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07J 3/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by one carbon atom
C07J 7/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
8.
Hexokinase 2-specific inhibitors for use in acute central nervous system injury
Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.
Disclosed is use of 5α-androst-3β,5,6β-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
A61K 38/36 - Blood coagulation or fibrinolysis factors
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
11.
USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING CEREBRAL SMALL VESSEL DISEASE
Disclosed is the use of 5α-androst-3β,5,6β-triol and analogs and deuterated compounds thereof or pharmaceutically acceptable salts thereof in the preparation of drugs for treating the cerebral small vessel disease of patients. The cerebral small vessel disease is preferably brain microhemorrhages. The brain microhemorrhages refer to spontaneous brain microhemorrhages, drug-related brain microhemorrhages or traumatic brain microhemorrhages. The present invention confirms that these compounds significantly enhance the clearance of extravascular hemoglobin and can thus be used for treating cerebral small vessel disease.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
12.
COMPOUND FOR TREATING INFLAMMATION-MEDIATED OPTIC NEUROPATHY
Disclosed is the use of 5α-androst-3β,5,6β-triol and analogs thereof, deuterated compounds thereof or pharmaceutically acceptable salts thereof in the preparation of drugs for treating inflammation-mediated optic neuropathy in patients. The present invention confirms that these compounds can significantly antagonize the activation of microglia and macrophages, and inhibit inflammatory responses so as to reduce the loss of rat optic ganglion cells caused by high intraocular pressure and to reduce the loss of axons of retinal ganglion cells, and can thus be used for treating inflammation-mediated optic neuropathy.
Disclosed is an application of 2β,3α,5α-trihydroxyl androstane-6-ketone and a deuterated compound thereof or pharmaceutically acceptable salts thereof in the preparation of drugs for treating inflammatory reactions of patients. The present invention proves that the 2β,3α,5α-trihydroxyl androstane-6-ketone inhibits the activation of microglial cells and macrophages by down-regulating the expression of inflammatory pathway key molecules NF-κB, and thus can used for treating inflammations.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
14.
APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATMENT OF HAEMORRHAGIC STROKE
Disclosed in the present invention are an application of 5α-androst-3β,5,6β-triol and an analogue, a deuterated substitute, or a pharmaceutically acceptable salt thereof in the preparation of a drug for the treatment of haemorrhagic stroke. The haemorrhagic stroke is a brain parenchymal haemorrhage, a subarachnoid haemorrhage, or both.
The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
16.
Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor
The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
18.
2β,3α,5α-trihydroxy-androst-6-one and preparation methods and use thereof
The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided are a use of 5α-androstane-3β,5,6β-triol and analogues thereof in the preparation of a drug for treating or preventing altitude sickness induced by hypobaric hypoxia.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 25/00 - Drugs for disorders of the nervous system
The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
The present invention provides a ketorolac implant and a method of preparing same. The implant comprises ketorolac and a degradable carrier, is prepared by adopting a hot melt extrusion method, can release drugs in a manner of zero-order kineics within a preset releasing time period, and can be used to prevent or treat acute and chronic ache and inflammation. The ketorolac implant prepared in the present invention has stable release, does not have a burst release effect, and has significant advantages in clinical use.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
22.
2β,3α,5α-TRIHYDROXY-ANDROST-6-ONE AND PREPARATION METHODS AND USE THEREOF
The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 25/00 - Drugs for disorders of the nervous system
A 5α-androstane (alkyl)-3β,5,6β-triol injection and preparation method therefor, the injection whereof using hydroxypropyl-β-cyclodextrin as a solubilizer and the active ingredient whereof being present preferably in a proportion by weight of 1-20:40-500 to the cyclodextrin. The injection may also comprise 1-100 parts of an isotonic regulator, 0-200 parts of a lyophilized filler, 0-2000 parts of a solvent. The preparation method comprises separately and successively dissolving the hydroxypropyl-β-cyclodextrin solution, the active ingredient and other soluble accessory ingredients in the water for injection, then after decolorization, depyrogenation, filtering, and sterilization of the filtrate, a liquid injection solution is obtained. Drying the filtrate yields a solid for injection.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Disclosed in the present invention is the use of 5α-androstane (alkyl)-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effects on neuron injuries induced by cerebral ischemia, spinal cord ischemia and hypoxia, and has no obvious toxic side effects under the effective dose thereof.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
25.
5.ALPHA.-ANDROSTANE-3.BETA.,5,6.BETA.-TRIOL INJECTION AND PREPARATION METHOD THEREFOR
A 5a-androstane (alkyl)-3ß,5,6ß-triol injection and preparation method therefor, the injection whereof using hydroxypropyl-ß-cyclodextrin as a solubilizer and the active ingredient whereof being present preferably in a proportion by weight of 1-20:40-500 to the cyclodextrin. The injection may also comprise 1-100 parts of an isotonic regulator, 0-200 parts of a lyophilized filler, 0-2000 parts of a solvent. The preparation method comprises separately and successively dissolving the hydroxypropyl-ß-cyclodextrin solution, the active ingredient and other soluble accessory ingredients in the water for injection, then after decolorization, depyrogenation, filtering, and sterilization of the filtrate, a liquid injection solution is obtained. Drying the filtrate yields a solid for injection.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Disclosed are four compounds of crystal form of androsta-3ß,5a,6ß-triol (YC-6 for short) (YC-6 of A crystal form, YC-6 of B crystal form, YC-6 of C crystal form, YC-6 of D crystal form) and a method for preparing same. The four compounds of crystal form are characterized by remarkable differences in parameters such as lattice parameters, 2? and intensity of X-ray powder diffraction, melting point, etc. Study on the polymorphism is significant for further researching the pharmaceutical effect, bioavailability and stability thereof.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
27.
HEXOKINASE 2-SPECIFIC INHIBITOR FOR TREATMENT OR PROPHYLAXIS OF ACUTE CENTRAL NERVOUS SYSTEM INJURY BY HYPOXIA-INDUCED MICROGLIA ACTIVATION
Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for prophylaxis or treatment of an acute central nervous system injury mediated by hypoxia-induced microglia activation.
The disclosure relates to compounds of Formula I, or a deuterated analog or a pharmaceutically acceptable salt thereof, wherein Ri is H, an alkyl or terminal alkenyl haying 1 to 5 carbon atoms, or -CH(CH3)(CH2)3CH(CH3)2: for use in treating hemorrhagic stroke, and for preparing medicaments for treating hemorrhagic stroke.
Disclosed is the use of compounds of formula I: (see formula I) a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient, wherein R1 is H, an alkyl having 1 to 5 carbon atoms, or -CH(CH3)(CH2)3CH(CH3)2. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
30.
USE OF 5.ALPHA.-ANDROSTANE(ALKYL)-3.BETA.,5,6.BETA.-TRIOL IN PREPARATION OF NEUROPROTECTIVE DRUGS
Disclosed is the use of 5.alpha.-androstane(alkyl)-3.beta.,5,6.beta.-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
Use of 5.alpha.-androstane-3.beta.,5,6.beta.-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5.alpha.-androstane-3.beta.,5,6.beta.-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
patents
